Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford team who have developed a COVID-19 vaccine in record time have been shortlisted for the Excellence in Healthcare Award at the NHS Parliamentary Awards.

Scientists analyzing covid 19 sample with microscope and holding covid 19 blood sample tube

The team from the Oxford Vaccine Group and Jenner Institute were nominated by Layla Moran, MP for Oxford West and Abingdon, and won the regional Excellence in Healthcare award.

The news coincided with announcement of interim data from phase III of the vaccine trial, which showed that the Oxford candidate vaccine was effective at preventing COVID-19 and offered a high level of protection. One dosing regimen indicated that the vaccine is 90 percent effective.

Layla Moran said:

"I'm absolutely delighted. There were nearly 700 nominations by MPs this year, so to be shortlisted is a huge achievement - the vaccine team really deserve it!

"The Oxford Vaccine Group and the Jenner Institute have been working so incredibly hard since the beginning of the pandemic to produce a vaccine that will be life changing for so many people around the world."

The NHS Parliamentary Awards are an annual opportunity to recognise and appreciate the very best about our local healthcare service.

The full story is available on the Oxford University Hospitals website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.